Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies
- PMID: 20865359
- DOI: 10.1007/s13277-010-0112-y
Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies
Abstract
Chemokines have been proposed to contribute to tumour growth and metastatic spread of several cancer entities. Here, we examined the relative levels of CXCL12/CXCR4 in resection specimens from patients with different malignant and non-malignant colorectal diseases as well as colorectal liver metastases (CRLM). CXCL12/CXCR4 mRNA and protein expression profiles were assessed by quantitative real-time PCR, Western blot analysis, enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry in resection specimens from patients with ulcerative colitis (UC; n = 15), colorectal adenoma (CRA; n = 15), colorectal adenocarcinoma (CRC; n = 47) and CRLM (n = 16). Corresponding non-affected tissues served as control. In contrast to UC tissues, CXCL12 showed a distinct down-regulation in CRA, CRC and CRLM specimens, whereas the corresponding receptor CXCR4 demonstrated a significant up-regulation in CRC and CRLM related to corresponding non-affected tissues (p < 0.05, respectively). Our results strongly suggest an association between CXCL12/CXCR4 expression and the induction of CRA, CRC and the development of CRLM. Therefore, CXCR4 may be a potential target for specific therapeutic interventions.
Similar articles
-
Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.Cancer Biomark. 2015;15(6):869-79. doi: 10.3233/CBM-150531. Cancer Biomark. 2015. PMID: 26406413
-
CCR6/CCL20 chemokine expression profile in distinct colorectal malignancies.Scand J Immunol. 2013 Sep;78(3):298-305. doi: 10.1111/sji.12087. Scand J Immunol. 2013. PMID: 23790181
-
ELR+ CXC chemokine expression in benign and malignant colorectal conditions.BMC Cancer. 2008 Jun 25;8:178. doi: 10.1186/1471-2407-8-178. BMC Cancer. 2008. PMID: 18578857 Free PMC article.
-
Differential CXC receptor expression in colorectal carcinomas.Scand J Immunol. 2008 Dec;68(6):635-44. doi: 10.1111/j.1365-3083.2008.02163.x. Epub 2008 Oct 6. Scand J Immunol. 2008. PMID: 18959627
-
Involvement of CXCL12/CXCR4 axis in colorectal cancer: a mini-review.Mol Biol Rep. 2023 Jul;50(7):6233-6239. doi: 10.1007/s11033-023-08479-1. Epub 2023 May 23. Mol Biol Rep. 2023. PMID: 37219666 Review.
Cited by
-
Clinicopathologic Significance of CXCL12 and CXCR4 Expressions in Patients with Colorectal Cancer.Gastroenterol Res Pract. 2018 May 16;2018:9613185. doi: 10.1155/2018/9613185. eCollection 2018. Gastroenterol Res Pract. 2018. PMID: 29887884 Free PMC article.
-
Identification of MicroRNA-Target Gene-Transcription Factor Regulatory Networks in Colorectal Adenoma Using Microarray Expression Data.Front Genet. 2020 May 19;11:463. doi: 10.3389/fgene.2020.00463. eCollection 2020. Front Genet. 2020. PMID: 32508878 Free PMC article.
-
CXCL12/CXCR4 display an inverse mRNA expression profile in gastric carcinoma that correlates with tumor progression.Oncol Lett. 2016 Jan;11(1):360-364. doi: 10.3892/ol.2015.3850. Epub 2015 Oct 30. Oncol Lett. 2016. PMID: 26870218 Free PMC article.
-
Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.Cancers (Basel). 2022 Apr 2;14(7):1810. doi: 10.3390/cancers14071810. Cancers (Basel). 2022. PMID: 35406582 Free PMC article. Review.
-
Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer.Cancer Immunol Immunother. 2015 Feb;64(2):181-90. doi: 10.1007/s00262-014-1624-x. Epub 2014 Oct 17. Cancer Immunol Immunother. 2015. PMID: 25324197 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical